Airlie Australian Share Fund quarterly update

Date Recorded: 7 October 2026

Ray presents the investment case for the new position in Dyno Nobel and outlines Airlie’s view on the Firmus IPO.

Key takeaways 

  • Emma believes single-stock volatility is here to stay. After an AI-driven repricing in February and a calmer August, the ASX 200 fell 2.4% in September as global bond yields spiked, and the portfolio fared worse as cyclical winners such as resources pulled back.
  • CSL was re-entered in early August after being exited earlier in the year. Anecdotal feedback from various quarters suggested CSL had turned the corner in immunoglobulin (IG), which generates approximately 40% of its revenue.
  • Dyno Nobel is a new position, supported by tight supply, improving demand, a growing defence earnings stream and a refreshed management team. Its $800 million EBIT target for 2031 implies a multiple of about 10 times, compared with 16–17 times for the average industrial.
  • Emma’s US trip showed AI-related capex is largely insensitive to interest rates, while consumers and rate-sensitive sectors are under pressure. Airlie remains patient on cyclicals such as James Hardie, where earnings can recover strongly when the cycle turns.
  • Airlie does not see an attractive risk/reward in the Firmus IPO, citing customer concentration, a highly geared balance sheet, an unproven management track record and uncertainty over GPU values beyond contract terms.

Important Information: Units in the fund referred to herein are issued by Magellan Asset Management Limited ABN 31 120 593 946, AFS Licence No. 304 301 trading as Magellan Investment Partners (‘Magellan’). This material is issued by Magellan and has been prepared for general information purposes only and must not be construed as investment advice or as an investment recommendation. This material does not take into account your investment objectives, financial situation or particular needs. This material does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should obtain and consider the relevant Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) and consider obtaining professional investment advice tailored to your specific circumstances before making a decision about whether to acquire, or continue to hold, the relevant financial product. A copy of the relevant PDS and TMD relating to the relevant Magellan financial product may be obtained by calling +61 2 9235 4888 or by visiting www.magellaninvestmentpartners.com.

Past performance is not necessarily indicative of future results and no person guarantees the future performance of the fund, the amount or timing of any return from it, that asset allocations will be met, that it will be able to implement its investment strategy or that its investment objectives will be achieved. Statements contained in this material that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of Magellan or the third party responsible for making those statements (as relevant). Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. This material may contain ‘forward-looking statements’. Actual events or results or the actual performance of a Magellan financial product or service may differ materially from those reflected or contemplated in such forward-looking statements. This material may include data, research and other information from third-party sources. No guarantee is made that such information is accurate, complete or timely and no warranty is given regarding results obtained from its use. This information is subject to change at any time and no person has any responsibility to update any of the information provided in this material. No representation or warranty is made with respect to the accuracy or completeness of any of the information contained in this material. Magellan will not be responsible or liable for any losses arising from your use or reliance upon any part of the information contained in this material. This material and the information contained within it may not be reproduced, or disclosed, in whole or in part, without the prior written consent of Magellan.

Further information regarding any benchmark referred to herein can be found at www.magellaninvestmentpartners.com/funds/benchmark-information/. (080825-#W14)